Literature DB >> 26289624

Outcomes for liver transplant candidates listed with low model for end-stage liver disease score.

Allison J Kwong1, Jennifer C Lai2, Jennifer L Dodge3, John P Roberts3.   

Abstract

The Model for End-Stage Liver Disease (MELD) score, which estimates mortality within 90 days, determines priority for liver transplantation (LT). However, longer-term outcomes on the wait list for patients who are initially listed with low MELD scores are not well characterized. All adults listed for primary LT at a single, high-volume center from 2005 to 2012 with an initial laboratory MELD score of 22 or lower were evaluated. Excluded were those patients listed with MELD exception points who underwent living donor liver transplantation (LDLT) or transplantation at another center, or who were removed from the wait list for nonmedical reasons. Outcomes and causes of death were identified by United Network for Organ Sharing, the National Death Index, and an electronic medical record review. Multivariate competing risk analysis evaluated predictors of death compared to deceased donor liver transplantation (DDLT); 893 patients were listed from 2005 to 2012. By the end of follow-up, 27% had undergone DDLT, and 31% were removed from the wait list for death or clinical deterioration. In a competing risks assessment, only MELD score of 6-9, older age, lower serum albumin, lower body mass index, and diabetes conferred an increased risk of wait-list dropout compared to DDLT. Listing for simultaneous liver-kidney transplantation was protective against wait-list dropout. Of the patients included, 275 patients died or were delisted for being too sick; 87% of the identifiable causes of death were directly related to end-stage liver disease or hepatocellular carcinoma. In conclusion, patients with low listing MELD scores remain at a significant risk for death due to liver-related causes and may benefit from early access to transplantation, such as LDLT or acceptance of high-risk donor livers. Predictors of death compared to transplantation may allow for early identification of patients who are at risk for wait-list mortality.
© 2015 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 26289624      PMCID: PMC4838198          DOI: 10.1002/lt.24307

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  16 in total

1.  Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death.

Authors:  Douglas M Heuman; Souheil G Abou-Assi; Adil Habib; Leslie M Williams; R Todd Stravitz; Arun J Sanyal; Robert A Fisher; Anastasios A Mihas
Journal:  Hepatology       Date:  2004-10       Impact factor: 17.425

2.  Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.

Authors:  Ma Somsouk; Rachel Kornfield; Eric Vittinghoff; John M Inadomi; Scott W Biggins
Journal:  Liver Transpl       Date:  2011-02       Impact factor: 5.799

3.  A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18.

Authors:  Maurizio Biselli; Marco Dall'Agata; Annagiulia Gramenzi; Stefano Gitto; Caterina Liberati; Lucia Brodosi; Matteo Ravaioli; Martina Gambato; Roberto Montalti; Antonio D Pinna; Patrizia Burra; Giorgio E Gerunda; Umberto Cillo; Pietro Andreone; Mauro Bernardi
Journal:  Liver Int       Date:  2014-04-08       Impact factor: 5.828

4.  High risk of delisting or death in liver transplant candidates following infections: Results from the North American Consortium for the Study of End-Stage Liver Disease.

Authors:  K Rajender Reddy; Jacqueline G O'Leary; Patrick S Kamath; Michael B Fallon; Scott W Biggins; Florence Wong; Heather M Patton; Guadalupe Garcia-Tsao; Ram M Subramanian; Leroy R Thacker; Jasmohan S Bajaj
Journal:  Liver Transpl       Date:  2015-07       Impact factor: 5.799

5.  Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list.

Authors:  Robert P Myers; Puneeta Tandon; Michael Ney; Glenda Meeberg; Peter Faris; Abdel Aziz M Shaheen; Alexander I Aspinall; Kelly W Burak
Journal:  Liver Int       Date:  2013-11-20       Impact factor: 5.828

6.  Serum hypoalbuminemia predicts late mortality on the liver transplant waiting list.

Authors:  Paige M Porrett; Esther Baranov; Matthijs ter Horst
Journal:  Transplantation       Date:  2015-01       Impact factor: 4.939

7.  Longitudinal assessment of mortality risk among candidates for liver transplantation.

Authors:  Robert M Merion; Robert A Wolfe; Dawn M Dykstra; Alan B Leichtman; Brenda Gillespie; Philip J Held
Journal:  Liver Transpl       Date:  2003-01       Impact factor: 5.799

8.  Model for end-stage liver disease (MELD) and allocation of donor livers.

Authors:  Russell Wiesner; Erick Edwards; Richard Freeman; Ann Harper; Ray Kim; Patrick Kamath; Walter Kremers; John Lake; Todd Howard; Robert M Merion; Robert A Wolfe; Ruud Krom
Journal:  Gastroenterology       Date:  2003-01       Impact factor: 22.682

9.  Stage of cirrhosis predicts the risk of liver-related death in patients with low Model for End-Stage Liver Disease scores and cirrhosis awaiting liver transplantation.

Authors:  Joel Wedd; Kiran M Bambha; Matt Stotts; Heather Laskey; Jordi Colmenero; Jane Gralla; Scott W Biggins
Journal:  Liver Transpl       Date:  2014-08-26       Impact factor: 5.799

10.  OPTN/SRTR 2012 Annual Data Report: liver.

Authors:  W R Kim; J M Smith; M A Skeans; D P Schladt; M A Schnitzler; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske
Journal:  Am J Transplant       Date:  2014-01       Impact factor: 8.086

View more
  12 in total

1.  Graft Reconditioning before Liver Transplantation.

Authors:  Dieter P Hoyer; Thomas Minor
Journal:  Visc Med       Date:  2016-07-29

2.  Neutrophil-to-lymphocyte ratio correlates with proinflammatory neutrophils and predicts death in low model for end-stage liver disease patients with cirrhosis.

Authors:  Avash Kalra; Joel P Wedd; Kiran M Bambha; Jane Gralla; Lucy Golden-Mason; Christine Collins; Hugo R Rosen; Scott W Biggins
Journal:  Liver Transpl       Date:  2017-02       Impact factor: 5.799

3.  Patients With Persistently Low MELD-Na Scores Continue to Be at Risk of Liver-related Death.

Authors:  Nikhilesh R Mazumder; Kofi Atiemo; Amna Daud; Abel Kho; Michael Abecassis; Josh Levitsky; Daniela P Ladner
Journal:  Transplantation       Date:  2020-07       Impact factor: 4.939

Review 4.  Selection of Patients for Initial Clinical Trials of Solid Organ Xenotransplantation.

Authors:  David K C Cooper; Martin Wijkstrom; Sundaram Hariharan; Joshua L Chan; Avneesh Singh; Keith Horvath; Muhammad Mohiuddin; Arielle Cimeno; Rolf N Barth; John C LaMattina; Richard N Pierson
Journal:  Transplantation       Date:  2017-07       Impact factor: 4.939

5.  Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation.

Authors:  Maria Baimas-George; Michael Watson; Jesse Sulzer; Patrick Salibi; Keith J Murphy; David Levi; John B Martinie; Dionisios Vrochides; Erin H Baker; Lee Ocuin; David A Iannitti
Journal:  Surg Endosc       Date:  2020-06-25       Impact factor: 4.584

6.  Living donor liver transplantation versus donation after brain death and donation after circulatory death liver transplantation in the US.

Authors:  Matthew Black; Amar Gupta; Sumeet K Asrani; Tsung-Wei Ma; Giuliano Testa; Anji Wall
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-03-09

Review 7.  Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.

Authors:  Yuval A Patel; Carl L Berg; Cynthia A Moylan
Journal:  Dig Dis Sci       Date:  2016-01-27       Impact factor: 3.199

8.  Accuracy of the Pediatric End-stage Liver Disease Score in Estimating Pretransplant Mortality Among Pediatric Liver Transplant Candidates.

Authors:  Chung-Chou H Chang; Cindy L Bryce; Benjamin L Shneider; Jonathan G Yabes; Yi Ren; Gabriel L Zenarosa; Heather Tomko; Drew M Donnell; Robert H Squires; Mark S Roberts
Journal:  JAMA Pediatr       Date:  2018-11-01       Impact factor: 16.193

Review 9.  A Comprehensive Review of Outcome Predictors in Low MELD Patients.

Authors:  Nikhilesh R Mazumder; Kofi Atiemo; Matthew Kappus; Giuseppe Cullaro; Matthew E Harinstein; Daniela Ladner; Elizabeth Verna; Jennifer Lai; Josh Levitsky
Journal:  Transplantation       Date:  2020-02       Impact factor: 5.385

Review 10.  The New Era of Transplant Oncology: Liver Transplantation for Nonresectable Colorectal Cancer Liver Metastases.

Authors:  Andre Gorgen; Hala Muaddi; Wei Zhang; Ian McGilvray; Steven Gallinger; Gonzalo Sapisochin
Journal:  Can J Gastroenterol Hepatol       Date:  2018-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.